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A B S T R A C T
MK571 is a multidrug resistance protein-2 (ABCC2, Mrp2) inhibitor and has been widely used to
demonstrate the role of Mrp2 in the cellular efﬂux of drugs, xenobiotics and their conjugates. Numerous
reports have described modulation of Caco-2 cellular efﬂux and transport of ﬂavonoids in the presence of
MK571. Since ﬂavonoids are efﬁciently conjugated by Caco-2/TC7 cells, we investigated the effects of
MK571 on the efﬂux of ﬂavonoid conjugates. The ﬂavonol aglycones kaempferol, quercetin and galangin
were efﬁciently taken up, conjugated and efﬂuxed by Caco-2/TC7 cells. Apically-applied MK571 caused
signiﬁcant reductions in both the apical and basolateral efﬂux of ﬂavonol conjugates from Caco-2/TC7
monolayers. MK571 did not signiﬁcantly alter the apical:basolateral efﬂux ratio for ﬂavonol conjugates,
however, which is not consistent with MK571 speciﬁcally inhibiting only apical Mrp2. Since MK571
decreased the total amounts of conjugates formed, and increased cellular ﬂavonol aglycone concentrations,
we explored the possibility that MK571 also inhibits phase-2 conjugation of ﬂavonols. MK571 dose-
dependently inhibited the intracellular biosynthesis of all ﬂavonol glucuronides and sulphates by Caco-2
cells. MK571 signiﬁcantly inhibited phase-2 conjugation of kaempferol by cell-free extracts of Caco-2, and
production of kaempferol-40-O-glucuronide was competitively inhibited. These data show that MK571, in
addition to inhibiting MRP2, is a potential inhibitor of enterocyte phase-2 conjugation.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Kaempferol, galangin and quercetin are ﬂavonoids belonging to
the sub-class ﬂavonols. Flavonols are secondary plant metabolites
present in plant tissues mostly in the form of glycosides. Flavonoids
are bioavailable in humans [1–7] and animals [8–11], and upon
ingestion, enter the small intestine where luminal hydrolysis of the
glycoside bond may occur for b-D-glucosides and b-D-galactosides,
by the brush border b-glucosidase lactase-phloridzin hydrolase
[12,13]. Following hydrolysis, the ﬂavonoid aglycone can diffuse
into the enterocytes [14]. Following cellular uptake of ﬂavonol
aglycones, extensive metabolism occurs within enterocytes which
leads to the formation of phase-II conjugates, most notably
sulphates and glucuronides, as well as methylated and mixed
conjugates [15–19]. The metabolism of ﬂavonoids has a major
impact on the chemical properties of ﬂavonols (e.g. molecular
mass, hydrophobicity) and on their biological activities, including
those that would be expected to confer health beneﬁts [20–25].
Conjugation also leads to a substantial increase in hydrophilicity,
and the subsequent efﬂux of ﬂavonoid conjugates from enterocytes
occurs via an active transport process [26,27].le under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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in the apical efﬂux of ﬂavonols based on the use of the Mpr2
inhibitor MK571 to inhibit apical transport of chrysin conjugates
[28], quercetin-40-b-glucoside [29], or cause cellular accumulation
of quercetin-40-b-glucoside [30,31]. In addition, quercetin glucur-
onides interacted with Mrp2 based on in silico calculations and on
experimental estimation of interactions of quercetin glucuronides
with Mrp2 expressed in ABCC2-overexpressing baculovirus-
infected Sf9 cells [32]. On the other hand, [33] used Madin–Darby
canine kidney-2 (MDCK-2) cells transfected with human Mrp2 and
reported no difference in the efﬂux of quercetin conjugates when
compared to control cells, suggesting Mrp2 is not involved in the
efﬂux of quercetin conjugates. The same authors demonstrated
that following intestinal uptake of quercetin, efﬂux of quercetin
glucuronides was no different between Mrp2 deﬁcient and control
rats.
The various reports providing evidence that ﬂavonols and their
phase-2 conjugates can interact with MRP2 and that treatment
with the Mrp2 inhibitor MK571 results in reduced rates of
transport/apical efﬂux are not consistent with evidence provided
by the [33] report which concluded that Mrp2 was not involved.
We hypothesised that MK571 interferes with ﬂavonol conjugation,
noting that if MK571 inhibited phase-2 conjugation of ﬂavonols,
then a reduction in apical efﬂux of these conjugates would be
observed. Therefore, we used Caco-2/TC7 cells, which efﬁciently
conjugate ﬂavonols, and investigated the potential for MK571 to
inﬂuence both the conjugation of ﬂavonols and their efﬂux from
the cells.
2. Materials and methods
All cell culture supplies were from Invitrogen, Paisley, UK,
unless otherwise stated. Caco-2/TC7 cells were kindly donated by
Dr M. Rousset, U178 INSERM, Villejuif, France. Millicell-ERS volt
ohmmeter was obtained from Millipore corporation, Massachu-
setts, USA. Transwell inserts and 12 well plates were Costar brand
obtained from Fisher Scientiﬁc, Loughborough, UK. The MK571
was purchased from Biomol Research Laboratories, Exeter, UK.
Mini protease inhibitor cocktail tablets containing EDTA and
perfabloc were purchased from Roche, Welwyn Garden City, UK.
Galangin, quercetin and kaempferol were purchased from Extra-
synthese, 69727 Genay Cedex, France. Alamethacin from Tricho-
derma viride, uridine 50-diphosphoglucuronic acid and uridine
50-diphospho-N-acetyl-glucosamine were purchased from Sigma–
Aldrich, Poole, UK. GraFit software was version 4.0 and purchased
from Erithacus Software Ltd., East Grinstead, UK. Gemini C18
(150 mm  2.0 mm i.d., 5 mm) narrow bore HPLC column was
purchased from Phenomenex, Macclesﬁeld, UK. Analytical chem-
istry was performed using ChemStation software on an HP1100
HPLC and single quadrupole MSD SL mass spectrometer from
Agilent, Manchester, UK. All solvents and other reagents of
analytical grade were obtained from Sigma–Aldrich, Poole, UK.
2.1. Cell culture
Cells were grown at 37 8C in a humidiﬁed incubator with 5% CO2
in Dulbecco Modiﬁed Eagle’s Medium (DMEM) containing 1% non-
essential amino acids, 1% L-glutamine, 100 IU/mL penicillin and
100 mg/mL streptomycin, 1 g/L glucose, and supplemented with
20% (v/v) heat inactivated fetal calf serum. Cells were passaged at
80% conﬂuency, and seeded at 2–4  104 cells per cm2 on 10 cm
dishes (growing area 75 cm2) or 12-well transwells (growing area
of 1.1 cm2). Cells were used for experiments when trans epithelial
electrical resistance values of wells showed values greater than
180 V/cm2 using a Millicell-ERS volt ohmmeter, which was
typically 21–23 days post conﬂuency. Toxicity of MK571 onCaco-2/TC7 cell monolayers was determined through comparison
of pre- and post-loading TEER values of wells incubated with
MK571.
2.2. Flavonol metabolism and transport experiments, and effects of
MK571
Flavonol stocks (quercetin, kaempferol, galangin; 10 mM) were
prepared in dimethylsulfoxide (DMSO) and stored at 20 8C.
MK571 was dissolved in dimethyl sulfoxide (10 mM ﬁnal
concentration) and stored at 20 8C. Prior to the metabolism or
transport experiments, cells were aspirated of media and washed
three times with phosphate buffered saline (PBS). To foetal calf
serum and phenol red-free DMEM was added ascorbic acid at a
ﬁnal concentration of 100 mM as well as MK571 at the desired
concentration. For metabolism experiments, 10 mL of this media
was added to the cells in 10 cm dishes. For transport experiments
using transwells, 0.6 mL of this media was added to the apical
compartment of the transwell and 1 mL was added to the
basolateral compartment. Control wells received an equivalent
dose of dimethyl sulfoxide as the treatment wells. Cells were
incubated at 37 8C for 30 min, after which ﬂavonols dissolved in
dimethyl sulfoxide (kaempferol, galangin or quercetin) were added
to the media of treatment wells at a ﬁnal concentration of 40
or 100 mM, while control wells were treated with the dimethyl
sulfoxide vehicle alone. Concentrations of quercetin were
increased to 100 mM because instability of quercetin in media
necessitated higher initial loading to maintain adequate cellular
and media concentrations for uptake and metabolism of the
ﬂavonol. Control and treatment cells were incubated at 37 8C for
the periods indicated in the results.
Following the required incubation period, media and cell
fractions were harvested and analysed to identify and quantify
ﬂavonol metabolites using HPLC. Media was removed from the
apical (0.5 mL) and basolateral (0.5 mL) compartments of trans-
wells and added to 25 mL triﬂuoroacetic acid and 25 mL HPLC grade
acetonitrile. Media from 10 cm dishes (1 mL) was removed and
added to 50 mL triﬂuoroacetic acid and 25 mL HPLC grade
acetonitrile. Cells were washed three times with cold (room
temperature) phosphate buffered saline solution and scraped free
of the dish surface. For transwells, 100 mL MilliQ water was added
to the cells and the resulting cell suspension pipetted into 10 mL
triﬂuoroacetic acid and 10 mL HPLC grade acetonitrile. For 10 cm
dishes, the resulting cell suspension was pipetted into 25 mL
triﬂuoroacetic acid and 25 mL HPLC grade acetonitrile. Samples
were either analysed immediately or otherwise stored at 20 8C
prior to HPLC analysis. Flavonols were stable during frozen storage
and thawing (no signiﬁcant losses up to 26 weeks).
2.3. Sample preparation and analytical chemistry
Media samples were thawed where necessary and then mixed
using a vortex mixer, centrifuged for 10 min at 14,000  g using a
micro centrifuge, and the supernatant removed and placed in
an HPLC vial for analysis. Cell samples were vortex-mixed and
then ultra-sonicated (sonic water bath) for 10 min, vortex mixed
again and then centrifuged for 10 min at 14,000  g using a micro-
centrifuge, before removal of supernatant for HPLC analysis.
Identiﬁcation and quantiﬁcation of individual ﬂavonol metabolites
was carried out using liquid chromatography–mass spectrometry
and nuclear magnetic resonance analyses, as described previously
[19]. The quantities of analytes (individual ﬂavonol conjugates or
total conjugates) present in the media from 10 cm dishes and
apical/basolateral media samples from transwells, and in cell
fractions, were calculated from the respective HPLC chromatogram
peak areas using standard curves generated with authentic
Fig. 1. The effect of MK571 on kaempferol conjugate efﬂux in clonal Caco-2/TC7
cells grown on 12 well transwell monolayers. The kaempferol aglycone (40 mM)
was incubated on Caco-2/TC7 monolayers with MK571. After 60 min samples of
media were taken from the apical compartments and analysed for kaempferol
glucuronide (-GlcA) and sulphate (-S) conjugates. *P < 0.05; **P < 0.01;
***P < 0.001; n = 4 for all data points.
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were not available.
2.4. Determination of apical (Ap) to basolateral (Bl) ratios from
transport experiments
The amount of each analyte was calculated for each of the apical
and basolateral compartments in transwell experiments, and rates
were calculated as pmol ﬂavonol conjugates min1 cm2 cells. The
apical to basolateral ratio was calculated using the following
equation:
Ap : Bl ratio
¼ molar quantity of analyte in apical compartment
molar quantity of analyte in basolateral compartment
2.5. Cell free assays and enzyme kinetics
Cells were grown until 21 days post conﬂuent and washed and
aspirated as described previously. The cells were then scraped into
tubes and these tubes kept on ice at all times throughout the
preparation procedure. Homogenisation buffer comprised of
sodium phosphate buffer (50 mM adjusted to pH 6.5; 20 mL),
two mini protease inhibitor cocktail tablets containing EDTA
and perfabloc, dithiothreitol (30.8 mg), alamethacin (20 mL of a
22 mg/mL) solution from T. viride; and MgCl2 (3.5 mg). Cell-free
homogenates were prepared by mixing cells with homogenisation
buffer (50:50, vol/vol) and vortexing with glass beads in an
eppendorf tube three times for 1 min over a 10 min period. To
900 mL of cell free lysate was added 10 mL uridine 50-dipho-
sphoglucuronic acid (4 mM ﬁnal concentration) with uridine
50-diphospho-N-acetyl-glucosamine (dissolved in homogenisation
buffer, 2 mM ﬁnal concentration); 10 mL MK571 (50 mmol/L stock
diluted 1:9 with homogenisation buffer) or 10 mL dimethyl
sulfoxide blank (diluted 1:9 with homogenisation buffer). The
tubes were allowed to warm and once they reached 37 8C, the
ﬂavonols were added at the relevant concentration (kaempferol,
quercetin or galangin; 10 mmol/L stock in dimethyl sulfoxide
diluted 1:1 with homogenisation buffer, plus homogenisation
buffer added to create a ﬁnal volume of 1000 mL) and the tube
vortexed brieﬂy. The experiment was stopped by addition of a
mixture of 50 mL triﬂuoracetic acid and 50 mL acetonitrile.
Samples were then centrifuged for 10 min at 14,000  g. The
supernatant was removed and analysed via HPLC.
2.6. Estimation of Km, Vmax and Ki values
Estimates of initial rates (v) of formation of ﬂavonol conjugates
by UDP-b-D-glucuronosyl transferase (UDP-GT) activity in the
Caco2 cell-free extracts were calculated for each concentration of S
(S = kaempferol; [S] range 5–150 mM). Reciprocal plots (1/v versus
1/S) were generated and examined for linear ﬁt. At concentrations
where good linear ﬁt in reciprocal plots was observed, Km and Vmax
values were estimated using the weighted least-squares linear
regression algorithm available in the GraFit software [34]. The type
of inhibition was determined by plotting 1/v versus 1/S for each of
the inhibitor (MK571) concentrations tested and observing the
location of the intersection of the lines, which also gave estimated
values for Km and Vmax. Subsequently, the slopes of the primary
reciprocal plots (y-axis) were plotted against the concentration of
inhibitor ([MK571], x-axis) and used to obtain the Ki:
Slope (of best ﬁt line) = Km/(Vmax  Ki)
y-Intercept = Km/Vmax
Ki = y-intercept/slope2.7. Statistical analyses
All statistical analysis was carried out using GraphPad online
software (www.graphpad.com) using an unpaired t-test, with a
P value of <0.05 as indicating statistical signiﬁcance. Application
of a Shapiro-Wilk test on each group of data was done prior to
application of the statistical test of signiﬁcance, and all of the
Shapiro-Wilk tests suggested that the data came from a normal
distribution.
3. Results
3.1. MK571 inhibits the rate of apical efﬂux of ﬂavonol conjugates
from Caco-2/TC7 monolayers
The effect of MK571 on the efﬂux of phase-2 conjugates
(sulphates, glucuronides and methylated derivatives) of ﬂavonols
(galangin, kaempferol, quercetin) from intestinal epithelial cells
was investigated using a differentiated Caco-2/TC7 cell model.
When Caco-2/TC7 cell monolayers were incubated with kaemp-
ferol in the absence of MK571, kaempferol-sulfo-glucuronide,
kaempferol-3-glucuronide, kaempferol-7-glucuronide, kaemp-
ferol-40-glucuronide, kaempferol-3-sulphate and kaempferol-7-
sulphate were formed. Details of their structural identiﬁcation are
reported elsewhere [19]. In the presence of MK571 (50 mM), the
amount of kaempferol conjugates efﬂuxed to the media was
signiﬁcantly (44%; P < 0.001) lower than in the absence of MK571,
and the inhibition was dose-dependent (Fig. 1). Similar reductions
in the appearance of ﬂavonol phase-2 conjugates in the culture
media were observed for the structurally similar ﬂavonols
quercetin (penta-hydroxy ﬂavonol) and galangin (trihydroxy
ﬂavonol). Compared to vehicle-only control incubations, addition
of MK571 (50 mM) to Caco-2/TC7 monolayers resulted in reduc-
tions of 41% and 38% in the efﬂux of quercetin and galangin to the
apical compartment, respectively (Figs. 2 and 3). Signiﬁcant
increases in the ﬂavonol aglycone concentrations of the cellular
extract accompanied the reductions in conjugates seen in the
apical compartments for kaempferol (+182%; P < 0.05), galangin
(+180%; P < 0.001) and quercetin (+119%; P < 0.05) with addition
of 50 mM MK571, and for kaempferol (+229%; P < 0.01) with
addition of 100 mM MK571.
Fig. 2. The effect of MK571 on quercetin conjugate efﬂux in clonal Caco-2/TC7 cells
grown on 12 well transwell monolayers. The quercetin aglycone (100 mM) was
incubated on Caco-2/TC7 monolayers with MK51. After 60 min samples of media
were taken from the apical compartments and analysed using for quercetin
glucuronide (-GlcA) and sulphate (-S) conjugates. *P < 0.05; **P < 0.01;
***P < 0.001; n = 6 for all data points.
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TC7 monolayers
The data presented in Figs. 2 and 3 shows that MK571 treatment
causes signiﬁcant and substantial reductions in the efﬂux of phase-
2 conjugates across the apical membranes of enterocyte mono-
layers of all three ﬂavonols tested. These data are in keeping with
MK571-induced inhibition of the apical efﬂux transporter Mrp-2.Fig. 3. The effect of MK571 on galangin conjugate efﬂux in clonal Caco-2/TC7 cells
grown on 12 well transwell monolayers. The galangin aglycone (40 mM) was
incubated on Caco-2/TC7 monolayers with MK51. After 60 min samples of media
were taken from the apical compartments and analysed for galangin glucuronide (-
GlcA) and sulphate (-S) conjugates. *P < 0.05; **P < 0.01; ***P < 0.001; n = 4 for all
data points.However, the observed MK571-induced reduction in accumulation
of ﬂavonol conjugates in the apical media of Caco-2/TC7
monolayers is also consistent with a reduction in the rate of
phase-2 metabolite formation. We examined the effects of MK571
on total conjugate production by summing the ﬂavonol conjugates
present in the apical, basolateral and cellular compartments at the
end of incubations with ﬂavanols in the presence or absence of
MK571. The data presented in Table 1 clearly show that for all three
ﬂavonols, the presence of MK571 caused signiﬁcant (P < 0.001)
reductions in the synthesis of phase-2 conjugates by the cells.
Furthermore, the magnitudes of the MK571-induced reductions
in ﬂavonol-conjugate production were very similar to the MK571-
induced reductions in apical efﬂux of the ﬂavonol conjugates.
Taken together, these observations provide indirect evidence to
support the notion that the MK571-induced decrease in apical
efﬂux of ﬂavonol conjugates was caused by MK571-mediated
inhibition of ﬂavanol conjugation by the enterocytes. For all
ﬂavonols, decreases in the total amounts of metabolites were
caused by lower amounts of both glucuronide and sulphate
conjugates. Production of total kaempferol glucuronides was
reduced by 52.3 and 67.2%, and kaempferol sulphates by
50.8 and 88.4% in the presence of 50 and 100 mM MK571,
respectively. Quercetin and galangin glucuronides were similarly
decreased by 56.5 and 42.8%, respectively, and quercetin and
galangin sulphates by 39.6% and 37.0%, respectively.
The small surface area of the 12 well transwell inserts made
detailed analysis of the cellular content of metabolites difﬁcult.
Therefore to assess the effect of MK571 on the conjugation of
individual kaempferol metabolites in more detail, kaempferol
was added to 10 cm dishes in order to generate larger amounts
of metabolites. Addition of MK571 caused signiﬁcant concentra-
tion-dependent reduction in the levels of kaempferol conjugates
at 60 min in both the media (Fig. 4) and cellular compartments
(Fig. 5).
3.3. MK571 does not decrease the apical to basolateral efﬂux ratio of
ﬂavonol glucuronides in transwell monolayers
If MK571 exclusively inhibits apical transport, it would be
expected that the apical efﬂux would be decreased relative to the
basolateral efﬂux, resulting in a decrease in the apical to
basolateral efﬂux ratio. Therefore, in order to determine the
degree of apical inhibition, the apical to basolateral efﬂux ratios
of the ﬂavonoid conjugates were measured in the presence and
absence of apical MK571. Apical to basolateral ratios for all ﬂavonol
glucuronide conjugates showed a dose dependent increase with
addition of MK571 (Table 2). Only kaempferol sulphate at the
100 mM concentration and galangin sulphate at the 50 mM
concentration showed reductions in the apical to basolateral ratio.
In order to further investigate the effect of MK571 on the
metabolism of ﬂavonol conjugates, cell free experiments using
Caco-2/TC7 homogenates were undertaken. Incubation of the
cell-free lysate with galangin and kaempferol resulted in signiﬁ-
cant reductions in production of kaempferol-3-glucuronide,
kaempferol-7-glucuronide, galangin-3-glucuronide and galangin-
7-glucuronide, in the presence of MK571 (Table 3).
3.4. The effect of MK571 on kaempferol-40-glucuronide conjugation
To investigate the effect of MK571 on the glucuronidation and
sulfation of individual kaempferol conjugates further, a range of
concentrations of aglycone were incubated with MK571 and the
cell lysate. Addition of MK571 resulted in concentration-depen-
dent reductions in the production of all kaempferol phase-II
conjugates. The Lineweaver–Burk reciprocal plots for each of the
glucuronidated products of kaempferol (O-b-D-glucuronides
Table 1
The effect of MK571 on ﬂavonol conjugation using 21-day post-conﬂuent Caco-2/TC7 cells grown on 12 well transwell inserts. MK571 was added to the apical media of
treatment wells at concentrations of 50 or 100 mM. Treatment and control (no MK571) wells were incubated with ﬂavonol (quercetin, kaempferol, galangin) for 60 min after
which apical and basolateral media and the cell fraction analysed for ﬂavonols and ﬂavonol glucuronides (-GlcA) and sulphates (-S) using HPLC. Data provided are rates (nmol/
h); n = 4 for kaempferol (incubation with 40 mM aglycone), n = 6 for quercetin (incubation with 100 mM aglycone), n = 4 for galangin (incubation with 40 mM aglycone);
kaempferol conjugates detected were K-S-GlcA, K-40-GlcA, K-3-GlcA, K-7-GlcA, K-S; quercetin conjugates detected were Q-7-GlcA, Q-3-GlcA, Q-30-GlcA, Q-40-GlcA, Q-7-S, Q-
3-S; galangin metabolites detected were G-5-GlcA, G-3-GlcA, G-7-GlcA, G-S.
Apical Basolateral Cellular Total conjugates
Kaempferol (K) 2.104 3.429 0.005 5.538
K + 50 mM MK571 1.196 (43.2%)* 1.484 (56.7%)* 0.004 (20.0%) 2.684 (51.5%)*
K + 100 mM MK571 0.382 (81.9%)*** 1.062 (69.0%)** 0.003 (24.2%) 1.447 (73.9%)**
Quercetin (Q) 1.122 2.916 0.004 4.042
Q + 50 mM MK571 0.706 (37.1%)*** 1.275 (56.3%)*** 0.004 (2.72%) 1.985 (50.9%)***
Galangin (G) 2.907 4.037 0.006 6.950
G + 50 mM MK571 1.789 (38.5%)** 2.279 (43.6%)*** 0.004 (28.7%)*** 4.072 (41.4%)***
* P < 0.05.
** P < 0.01.
*** P < 0.001.
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GlcA) were different. However, substrate inhibition occurred at the
higher concentrations of kaempferol, except for kaempferol-40-
glucuronide (K-40-O-GlcA) where the data gave a reasonable ﬁt to
the Michaelis–Menten curve and Km and Vmax values were easy to
estimate. In the presence of increasing concentrations of MK571,
the Vmax for synthesis of K-40-O-GlcA remained unaffected but the
Kmwas increased (=decreased afﬁnity). This observation is entirely
consistent with competitive inhibition of the synthesis of K-40-O-
GlcA by MK571. The estimated Ki for inhibition of the synthesis of
K-40-O-GlcA by MK571 was 19.7 mM.
4. Discussion
Efﬂux of ﬂavonol conjugates back to the lumen of the gut
contributes to a reduction in overall absorption of ﬂavonols. Here
we show that the addition of the Mrp2 inhibitor MK571 apically to
Caco-2/TC7 monolayers resulted in a reduction in the efﬂux ofFig. 4. The effect of MK571 on kaempferol metabolism in clonal Caco-2/TC7 cells
grown on 10 cm dishes. Kaempferol aglycone (40 mM) was incubated in Caco-2/TC7
cells grown on 10 cm dishes with 25, 50 and 100 mM of MK51. After 60 min samples
were taken from the media and analysed for kaempferol glucuronide (-GlcA) and
sulphate (-S) conjugates. K-S-GlcA was not detected. *P < 0.05; **P < 0.01;
***P < 0.001; n = 3 for all data points.ﬂavonol conjugates to the apical compartment, as well as
decreased quantities inside cells and on the basolateral side.
These ﬁndings are not consistent with a speciﬁc effect of MK571
only on apical transport as reported for many compounds
previously. Instead, our observations are more consistent with
an inhibitory effect of MK571 on the cellular conjugation of the
ﬂavonols, i.e. by inhibition of UDP-glucuronosyl transferases and
aryl-sulfatases. In support of this, measurement of the rate of
production of ﬂavonol conjugates using a Caco-2/TC7 cell-free
extract demonstrated the direct inhibitory effects of MK571 on
conjugation production.
Our results show that apical efﬂux of quercetin, galangin and
kaempferol conjugates from Caco-2/TC7 transwell monolayers are
reduced by 37.1, 38.5 and 43.2%, respectively, in the presence of
50 mM MK571. In a similar way, chrysin glucuronide and sulphate
efﬂux was inhibited by 71% and 25%, respectively, in the presence
of 50 mM MK571 in Caco-2 cells (Walle et al. [28]). Further, efﬂux
of methylated sulphate conjugates of epigallocatechin andFig. 5. The effect of MK571 on kaempferol metabolism in clonal Caco-2/TC7 cells
grown on 10 cm dishes. Kaempferol aglycone was incubated in Caco-2/TC7 cells
grown on 10 cm dishes with 25, 50 and 100 mM of MK51. After 60 min samples of
cells were taken and analysed for kaempferol glucuronide (-GlcA) and sulphate (-S)
conjugates. *P < 0.05; **P < 0.01; ***P < 0.001; n = 3 for all data points.
Table 2
The effect of MK571 on the apical to basolateral ratio of efﬂux of ﬂavonol conjugates
by conﬂuent Caco-2/TC7 cells grown on 12-well transwells. MK571 was added to
the media of treatment wells at concentrations of 50 or 100 mM. Treatment and
control (no MK571) wells were incubated with ﬂavonol (quercetin, kaempferol,
galangin) for 60 min after which apical and basolateral media and the cell fraction
analysed for ﬂavonols and ﬂavonol glucuronides (-GlcA) and sulphates (-S) using
HPLC. All data are rates (pmol/h). n = 4 for kaempferol, n = 6 for quercetin and
galangin. N/D = not determined.
Metabolite Ap:Bl ratio
(No MK571)
Ap:Bl ratio
(50 mM MK571)
Ap:Bl ratio
(100 mM MK571)
K-S-GlcA 0.59 (0.174) 0.42 (0.121) 0.43 (0.028)
K-3-GlcA 0.22 (0.040) 0.33 (0.057)* 0.35 (0.063)**
K-7-GlcA 0.28 (0.044) 0.35 (0.063) 0.44 (0.021)**
K-40-GlcA 0.26 (0.066) 0.33 (0.080) 0.43 (0.018)*
K-S 3.02 (0.230) 3.92 (0.646) 0.14 (0.006)***
Q-7-GlcA 0.18 (0.024) 0.20 (0.019) N/D
Q-3-GlcA 0.17 (0.021) 0.23 (0.023)*** N/D
Q-30-GlcA 100% apical 100% apical N/D
Q-40-GlcA 0.23 (0.034) 0.25 (0.035) N/D
Q-7-S 1.37 (0.095) 1.50 (0.134) N/D
Q-3-S 0.84 (0.086) 1.01 (0.191) N/D
G-5-GlcA 0.19 (0.020) 0.30 (0.024)*** N/D
G-3-GlcA 0.24 (0.033) 0.35 (0.091)* N/D
G-7-GlcA 0.54 (0.058) 0.51 (0.036) N/D
G-S 13.6 (1.440) 9.10 (0.783)*** N/D
* P < 0.05.
** P < 0.01.
*** P < 0.001.
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ited in the presence of 50 mM MK71 [35], and apical efﬂux of
epicatechin sulphate conjugates was inhibited by >50% [36]. These
studies concluded that Mrp2 played a major role ﬂavonoid
conjugate efﬂux, supported by inhibition studies using Mrp2-
over-expressing cells and in silico modelling (Williamson et al.
[32]). Using more detailed analysis, here we show that in addition
to these inhibitory activities, inhibition of phase 2 conjugation is
also important, and may even predominate for ﬂavonols when
used in a Caco-2/TC-7 monolayer model of intestinal absorption.
The TC7 clone of Caco-2 cells is much more efﬁcient than
‘‘conventional’’ clones at phase 2 conjugation including higher
expression of all SULTs [37] and of some UGT isoforms
[38]. Therefore, the activity of MK571 on phase 2 conjugating
enzymes may be shifted in conjugation-competent cells, and this
interaction is potentially missed in the other Caco-2 lines. ApigeninTable 3
The effect of MK571 on the rate of ﬂavonol conjugate production by cell free lysate
using 21 days post-conﬂuent Caco-2/TC7 cells. Portions of Caco-2/TC7 cell lysate
were incubated with kaempferol, quercetin or galangin aglycones (each at 40 mM)
in the presence or absence of MK571 (50 mM) and samples taken at various time
points and analysed for ﬂavonol glucuronides (-GlcA) and sulphates (-S) using
HPLC. All rate data are the slopes (linear best ﬁt) of the plots of amount of product
versus time (pmol/h). Parentheses indicate the standard error of the slope; n = 3 for
all data points.
Metabolite Rate
control
Rate
+MK571
Change in
rate (%)
P value
K-S-GlcA 0.54 (0.04) 0.34 (0.02) 40.0% 0.124
K-3-GlcA 1.73 (0.16) 1.40 (0.08)** 19.3% 0.007
K-7-GlcA 1.12 (0.09) 0.69 (0.02)*** 38.2% 0.000
Q-7-GlcA 1.89 (0.16) 1.29 (0.26) 31.8% 0.299
Q-3-GlcA 1.05 (0.09) 0.83 (0.14) 21.8% 0.398
Q-30-GlcA 2.09 (0.12) 2.62 (0.24) +25.6% 0.291
Q-40-GlcA 0.25 (0.01) 0.28 (0.03) +12.1% 0.493
G-3-GlcA 68.8 (6.12) 25.3 (2.30)** 63.2% 0.003
G-7-GlcA 36.5 (1.49) 19.8 (1.63)** 45.7% 0.002
*P < 0.05.
** P < 0.01.
*** P < 0.001.glucuronidation was inhibited by 30–40% in the presence of 50 mM
MK571, whereas sulfation was not inhibited [39].
Examination of kinetics using a range of kaempferol and MK571
concentrations with Caco-2/TC7 cell free lysate showed a MK571-
concentration-dependent reduction in the production of all
kaempferol phase-II conjugates, with apparent substrate inhibi-
tion at high concentrations of kaempferol. The exception was for
kaempferol-40-glucuronide, where the data gave a reasonable ﬁt
to the Michaelis–Menten curve, with competitive inhibition by
MK571. This is the ﬁrst report of competitive inhibition of MK571
on the glucuronidation of ﬂavonoids and the ﬁrst time it has been
demonstrated that MK571 causes inhibition of both glucuronsyl-
transferase and aryl-sulfatase enzymes. The apparent substrate
inhibition observed in cell-free extract incubations could also
account for the inhibition of glucuronidation and sulfation seen in
Caco-2/TC7 transwell experiments. The observation that cellular
concentrations of ﬂavonol aglycone increased with addition of
MK571 is consistent with this line of reasoning, and substrate
inhibition by the parent aglycone accumulating in the cells may
therefore account for some of the inhibitory effect on ﬂavonoid
conjugation. Nevertheless, the lack of effect of MK571 treatment
on the apical:basolateral ratios for any of the ﬂavonol conjugates
conﬁrms that MK571 is not speciﬁcally affecting efﬂux transport of
the ﬂavonol conjugates (and in particular MRP-2 mediated efﬂux
to the apical compartment) and that its major effect is to reduce the
rate of conjugation of ﬂavonols. Although the potential inhibitory
effects of MK571 on individual UGT isoforms were not tested in
this study, this is something that could be explored in future work.
Mrp2 is not essential for the apical efﬂux of ﬂavonol conjugates
in some cases. Using Mrp2 deﬁcient rats, luminal efﬂux of
quercetin glucuronides and plasma levels of quercetin did not
differ between control rats, suggesting that another transporter
was responsible for the effect [33]. The breast cancer resistance
protein 1 (Bcrp1; ABCC3) may be involved in apical efﬂux of
quercetin from enterocytes as shown using Mrp2 deﬁcient rats
where the Bcrp1 inhibitor FTC increased total plasma quercetin
and isorhamnetin concentrations to twice that of controls [33], and
the role of Bcrp1 was supported by apical efﬂux of quercetin in
mouse Bcrp1 transfected (MDCK)II cell monolayers but with no
directional transport of quercetin in either human Mrp2 trans-
fected MDCKII or parental (MDCK)II monolayers. However, no
conjugates could be detected in either the apical or basolateral
compartment of the transfected or parental (MDCK)II cells, and so
only efﬂux of quercetin aglycone was observed, which suggests
that the cells did not contain UDP-glucuronosyl transferase nor
aryl-sulfatase activity.
The metabolism by intestinal cells involves uptake of the
aglycone, conjugation by phase 2 enzymes, and efﬂux by Mrp2,
Bcrp1 or other transporters. In cell models, the ratio of activities of
these three steps will vary between different cell lines and
different clones. In TC7 cells, phase 2 conjugation is increased
relative to other cells, and hence this step is increased in
importance as a target for an inhibitor. It is also possible that
the effects of MK571 on phase-2 conjugation described here on
Caco-2/TC7 cells are not replicated in other cell types, for example
because the effects are speciﬁc to the enzymes expressed in CaCo2
cells or the small intestine, and other isoforms of the enzymes may
not be affected in the same way. Further research to establish the
effects of MK571 on phase-2 conjugation in other cell types and
the characterisation of the susceptibility of the various isoforms
of UDP-glucuronosyltransferase and aryl-sulfatase is warranted.
MK571 may cause inhibition of glucuronidation and apical
transport at the concentrations previously used in transport
studies (50 mM), but at lower concentrations (10 mM), the effects
on glucuronidation may be attenuated somewhat [39]. Further, the
identiﬁcation of Mrp2 in the transport of ﬂavonoid aglycones and
R.D. Barrington et al. / Biochemical Pharmacology 95 (2015) 193–200 199glycosides based on inhibition studies using MK571 in Caco-2
transwell monolayer studies is complicated because MK571 has
been reported to show inhibition of Mrp1 [40], Mrp2, [41], Mrp4
[42], Mrp5 [42], and organic anion transporters (OAT) [41,43] and
may therefore have broad efﬂux pump activity. While Mrp1 is not
extensively expressed in Caco-2 cells [28], it cannot be discounted
that MK571 is able to inhibit the activity of multidrug resistant
proteins other than Mrp2 in Caco-2 cells. In addition, Bcrp1 has
been shown to be responsible for efﬂux of some other ﬂavonoids
such as hesperetin conjugates [44].
In conclusion, we have shown that conjugation of kaempferol,
quercetin and galangin in Caco-2/TC7 cells is inhibited in the
presence of the Mrp2 inhibitor MK571. Such inhibition may be due
to competitive inhibition of the UGT enzyme by MK571 or may
result from substrate inhibition by the ﬂavonol aglycone. This
inhibition seems to dominate the metabolic pathway and diminish
the signiﬁcance of inhibition of Mrp2, the classical target for
MK571. The data presented here suggest that the role of Mrp2 in
the efﬂux of ﬂavonol conjugates may have been overestimated
where effects on conjugation have not been taken into account.
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